Sujets)
Adolescent , Adulte , Sujet âgé , Enfant , Femelle , Humains , Mâle , Adulte d'âge moyen , Athérosclérose/thérapie , Cholestérol/sang , Dyslipidémies/thérapie , Athérosclérose/prévention et contrôle , Marqueurs biologiques/sang , Maladies cardiovasculaires/étiologie , Cholestérol ester/sang , Dyslipidémies/sang , Dyslipidémies/prévention et contrôle , Acides gras/métabolisme , Acides fibriques/métabolisme , Hypercholestérolémie/sang , Hypertriglycéridémie/sang , Espérance de vie , Lipoprotéines/métabolisme , Facteurs de risque , Triglycéride/sangRésumé
Etofibrate is a hybrid drug which combines niacin with clofibrate. After contact with plasma hydrolases, both constituents are gradually released in a controlled-release manner. In this study, we compared the effects of etofibrate and controlled-release niacin on lipid profile and plasma lipoprotein (a) (Lp(a)) levels of patients with triglyceride levels of 200 to 400 mg/dl, total cholesterol above 240 mg/dl and Lp(a) above 40 mg/dl. These patients were randomly assigned to a double-blind 16-week treatment period with etofibrate (500 mg twice daily, N = 14) or niacin (500 mg twice daily, N = 11). In both treatment groups total cholesterol, VLDL cholesterol and triglycerides were equally reduced and high-density lipoprotein cholesterol was increased. Etofibrate, but not niacin, reduced Lp(a) by 26 percent and low-density lipoprotein (LDL) cholesterol by 23 percent. The hybrid compound etofibrate produced a more effective reduction in plasma LDL cholesterol and Lp(a) levels than controlled-release niacin in type IIb dyslipidemic subjects